Venous Thromboembolism

The anticoagulant did not improve clinical outcomes when compared with prophylactic anticoagulation.

Patients on atorvastatin experienced similar rates of adjudicated venous thromboembolism and all-cause mortality compared to placebo.

A new study finds patients with atrial fibrillation or venous thromboembolism were at higher risk of increased bleeding and hospitalization when treated with combination DOAC and aspirin.

FDA, CDC recommended halting use of the one-shot vaccine at all federal sites.

Investigators evaluated patients from 3 Chicago hospital systems and assessed risk factors associated with thrombosis.

Liquidia Technologies plans on addressing FDA concerns regarding treprostinil.

Compared with prophylaxis anticoagulation, full dose anticoagulation provided a greater survival benefit to those in a predominantly black population.

The risk of VTE is increased in both hospitalized and non-hospitalized COVID-19 patients.

For obese patients, both weight gain and loss was linked to an increase in the rate of incident venous thromboembolism.

Treatments for VTE in children fall short as they require frequent monitoring and include unpredictable food and drug interactions.

Post-discharge thromboprophylaxis is not necessary.

The rate of adverse events was higher in patients suffering from both deep vein thrombosis and pulmonary embolisms than it was in just patients with DVT.

Future studies are needed to develop and validate better risk assessment tools.

Guideline adoption could lead to more use of thrombolytic therapy.

The study paves the way for prospective multi-institutional randomized control trials to further re-enforce the safe use of direct oral anticoagulants in patients with obesity.

A discussion on how thromboembolism research and care could benefit from progression in diagnostics.

Patients with a mPAP of at least 19 mm Hg and pulmonary artery wedge pressure of 15 mm Hg or less had an adjusted hazard ratio for mortality of 1.71.

A new systematic review and meta-analysis challenges the notion that preventing VTE is associated reduced mortality risk.

New findings evidences the device commonly used treatment in patients with VTE—despite its association with potentially new DVT development or existing DVT propagation.

An expert explains why little progress has been made in disease prevalence and burden in the US.

A new randomized trial suggests oral apixaban may be as effective as enoxaparin for thromboprophylaxis following surgery for gynecologic cancer.

A new systematic review and meta-analysis is shedding light on the impact gestational hypertension can have on future risk of cardiovascular diseases.

An analysis of the MARINER trial is diving deeper into the impact of post-discharge prophylaxis with rivaroxaban in patients with more severe renal impairment.